Senti Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Senti Biosciences
SNTI Stock  USD 1.03  0.03  2.83%   
Senti Biosciences' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Senti Biosciences' valuation are provided below:
Gross Profit
-37.6 M
Market Capitalization
27.1 M
Enterprise Value Revenue
134.2161
Revenue
338 K
Earnings Share
(2.87)
We have found one hundred twenty available fundamental trend indicators for Senti Biosciences, which can be analyzed and compared to other ratios and to its competition. Traders should compare all of Senti Biosciences current fundamentals against the fundamentals between 2010 and 2026 to make sure the company is sustainable this year. The current Market Cap is estimated to decrease to about 17.6 M. Enterprise Value is estimated to decrease to about 33.9 M

Senti Biosciences Total Revenue

0.0

Check Senti Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Senti Biosciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.8 M, Interest Expense of 4.7 M or Selling General Administrative of 25.1 M, as well as many indicators such as Price To Sales Ratio of 16.18, Dividend Yield of 0.0 or PTB Ratio of 0.69. Senti financial statements analysis is a perfect complement when working with Senti Biosciences Valuation or Volatility modules.
  
Build AI portfolio with Senti Stock
Check out the analysis of Senti Biosciences Correlation against competitors.
For more detail on how to invest in Senti Stock please use our How to Invest in Senti Biosciences guide.

Senti Biosciences Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets106.2 M112.5 M65.9 M
Slightly volatile
Other Current Liabilities6.8 M7.2 M4.7 M
Slightly volatile
Total Current Liabilities12.4 M15.1 M7.9 M
Slightly volatile
Property Plant And Equipment Net39.8 M40.5 M26.3 M
Slightly volatile
Accounts Payable1.6 M1.3 M1.5 M
Slightly volatile
Cash42.8 M55.5 M22.3 M
Slightly volatile
Non Current Assets Total43.4 M44.7 M27.9 M
Slightly volatile
Other Assets1.091.15738.8 K
Very volatile
Cash And Short Term Investments52.6 M55.5 M32.7 M
Slightly volatile
Net Receivables3.9 M2.1 M1.6 M
Slightly volatile
Common Stock Shares Outstanding4.3 M5.3 M2.7 M
Slightly volatile
Other Current Assets6.2 M10.2 M3.4 M
Slightly volatile
Other Stockholder Equity389.8 M371.2 M100.3 M
Slightly volatile
Total Liabilities62.3 M83 M38 M
Slightly volatile
Total Current Assets62.7 M67.8 M37.7 M
Slightly volatile
Common Stock1.1 K1.1 K1.4 K
Slightly volatile
Property Plant Equipment33.5 M64.6 M28.3 M
Slightly volatile
Short and Long Term Debt Total31.9 M38.7 M21 M
Slightly volatile
Current Deferred Revenue976.3 K594 K1.6 M
Slightly volatile
Liabilities And Stockholders Equity119.5 M112.5 M74 M
Slightly volatile
Non Current Liabilities Total41.3 M53.1 M80.9 M
Slightly volatile
Capital Lease Obligations31.9 M38.7 M21 M
Slightly volatile
Inventory366 K385.2 K446.4 K
Slightly volatile
Property Plant And Equipment Gross44.1 M51.5 M27.5 M
Slightly volatile
Capital Stock1.1 K1.1 K1.4 K
Slightly volatile
Net Working Capital57.5 M52.7 M37.6 M
Slightly volatile
Short Term Debt3.1 M5.5 M2.2 M
Slightly volatile
Other Liabilities467.2 K335.7 K674.2 K
Slightly volatile
Common Stock Total Equity3.2 K3.6 K3.9 K
Slightly volatile
Capital Surpluse240.4 M270.5 M295.2 M
Slightly volatile
Non Current Liabilities Other6.1 M5.8 M1.3 M
Slightly volatile

Senti Biosciences Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization3.8 M6.7 M2.1 M
Slightly volatile
Selling General Administrative25.1 M27 M15 M
Slightly volatile
Other Operating Expenses58.7 M70.2 M38 M
Slightly volatile
Research Development28.1 M39.5 M20.7 M
Slightly volatile
Cost Of Revenue6.8 M4.7 M11.2 M
Slightly volatile
Total Operating Expenses56.1 M70.2 M29.3 M
Slightly volatile
Net Interest Income1.4 M1.1 M569 K
Slightly volatile
Interest Income1.4 M1.1 M569 K
Slightly volatile
Reconciled Depreciation4.3 M6.7 M3 M
Slightly volatile
Non Operating Income Net Other8.6 M9.6 M10.5 M
Slightly volatile
Selling And Marketing Expenses3.3 M3.8 M4.1 M
Slightly volatile

Senti Biosciences Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation1.9 M2 M2.1 M
Slightly volatile
Other Cashflows From Financing Activities4 M4.2 M21.4 M
Pretty Stable
Depreciation4 M6.7 M2.6 M
Slightly volatile
Capital Expenditures28.4 K29.9 K4.7 M
Pretty Stable
Total Cash From Financing Activities53.8 M61.8 M31.5 M
Slightly volatile
End Period Cash Flow45.5 M59.6 M23.9 M
Slightly volatile
Begin Period Cash Flow43.2 M45.4 M20.2 M
Slightly volatile
Issuance Of Capital Stock23.6 M44.2 M30.3 M
Very volatile
Dividends Paid441.4 K464.6 K408 K
Slightly volatile
Sale Purchase Of Stock389.4 K588.8 K267.7 K
Slightly volatile
Cash And Cash Equivalents Changes1.4 M1.5 M1.7 M
Slightly volatile
Cash Flows Other Operating11.6 M13.1 M14.2 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio16.1817.031 K
Slightly volatile
Days Sales Outstanding3.1 K2.9 K962
Slightly volatile
Stock Based Compensation To Revenue2.244.42.7774
Slightly volatile
Capex To Depreciation0.00380.0041.7358
Very volatile
EV To Sales17.1418.04979
Slightly volatile
Payables Turnover9.710.9211.9191
Slightly volatile
Sales General And Administrative To Revenue32.6420.2758.6112
Slightly volatile
Research And Ddevelopement To Revenue17.7618.69108
Slightly volatile
Capex To Revenue10.467.016.6125
Slightly volatile
Cash Per Share13.5612.0812.8071
Very volatile
Days Payables Outstanding24.0627.0729.5502
Slightly volatile
Income Quality0.890.90.8494
Pretty Stable
Current Ratio5.635.164.747
Slightly volatile
Receivables Turnover0.09550.11.3266
Very volatile
Capex Per Share0.00480.00511.6688
Very volatile
Revenue Per Share0.30.40.2106
Slightly volatile
Interest Debt Per Share5.226.594.5096
Slightly volatile
Debt To Assets0.220.310.2839
Pretty Stable
Operating Cycle3.1 K2.9 K962
Slightly volatile
Days Of Payables Outstanding24.0627.0729.5502
Slightly volatile
Ebt Per Ebit1.050.990.97
Very volatile
Quick Ratio5.635.164.747
Slightly volatile
Net Income Per E B T1.110.981.1194
Slightly volatile
Cash Ratio2.813.312.2505
Slightly volatile
Cash Conversion Cycle3.1 K2.9 K944
Slightly volatile
Days Of Sales Outstanding3.1 K2.9 K962
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.030.91.1553
Very volatile
Fixed Asset Turnover0.03050.04280.021
Slightly volatile
Debt Ratio0.220.310.2839
Pretty Stable
Price Sales Ratio16.1817.031 K
Slightly volatile
Asset Turnover0.0110.01490.0078
Slightly volatile

Senti Biosciences Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap17.6 M18.6 M139.2 M
Pretty Stable
Enterprise Value33.9 M35.7 M134.8 M
Pretty Stable

Senti Fundamental Market Drivers

Senti Upcoming Events

27th of March 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Senti Biosciences Financial Statements

Investors use fundamental indicators, such as Senti Biosciences' revenue or net income, to determine how well the company is positioned to perform in the future. Although Senti Biosciences' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Current Deferred Revenue594 K976.3 K
Cost Of Revenue4.7 M6.8 M
Stock Based Compensation To Revenue 4.40  2.24 
Sales General And Administrative To Revenue 20.27  32.64 
Research And Ddevelopement To Revenue 18.69  17.76 
Capex To Revenue 7.00  10.46 
Revenue Per Share 0.40  0.30 
Ebit Per Revenue(42.19)(44.30)

Currently Active Assets on Macroaxis

WDWalker Dunlop
GMGeneral Motors
GMGeneral Motors
BACBank of America
SSentinelOne
When determining whether Senti Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Senti Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Senti Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Senti Biosciences Stock:
How To Invest In Senti
Details
Is Senti Stock a good investment?
Details
What is Senti Biosciences' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Senti Biosciences Correlation against competitors.
For more detail on how to invest in Senti Stock please use our How to Invest in Senti Biosciences guide.
You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is there potential for Biotechnology market expansion? Will Senti introduce new products? Factors like these will boost the valuation of Senti Biosciences. If investors know Senti will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Senti Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.87)
Revenue Per Share
0.075
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.68)
Return On Equity
(3.95)
The market value of Senti Biosciences is measured differently than its book value, which is the value of Senti that is recorded on the company's balance sheet. Investors also form their own opinion of Senti Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Senti Biosciences' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Senti Biosciences' market value can be influenced by many factors that don't directly affect Senti Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Senti Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Senti Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Senti Biosciences' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY